MediMap Bio, a company developing immunotherapy, announced on the 13th that it won first place at Innovation Tiger 2025, a pharmaceutical and bio startup competition held at Shonan Health Innovation Park, Japan's largest bio cluster.
MediMap Bio was selected as an invited company in July and advanced to the finals. They won the final pitch on September 30th. As a result, they received 3 million yen in prize money and an invitation to the Shonan Health Innovation Conference (SHIC 2025), a global biotechnology event to be held in Boston, USA in November.
This event, designed to discover promising biotech startups in the Asian region, saw the participation of 79 companies from Korea, Japan, Taiwan, and other countries, of which 16 advanced to the finals. Eight Japanese and global pharmaceutical companies, including MSD, Takeda, Eli Lilly, Eisai, and Astellas, participated in the judging process, evaluating the technologies, commercialization potential, and potential for investment and joint research expansion.
MediMap Bio presented its pipeline of immuno-oncology and autoimmune disease treatments currently under development, leveraging its AI-based immunotherapy platform. The panel of judges highly evaluated the technology's uniqueness, drug efficacy, and safety.
This award provides MediMap Bio with the opportunity to participate in SHIC, which offers one-on-one meetings with global pharmaceutical companies and venture capitalists. This, in turn, is expected to expand its overseas partnerships and attract investment. MediMap Bio is currently a resident company of Seoul Bio Hub, a biotech startup support platform operated by the Seoul Metropolitan Government. Utilizing its research infrastructure and support programs, the company is pursuing technological advancement and expanding its global collaboration base.
“This award is a recognition of our technological prowess and global growth potential,” said Kang Yoo-hoe, CEO of MediMap Bio. “We plan to actively explore opportunities for overseas expansion and strategic collaboration for our immunotherapy platform through our participation in SHIC.”
- See more related articles
You must be logged in to post a comment.